This webinar takes place on Tuesday June 9 between 16.00 and 16.30 CEST / 15.00-15.30 GMT / 10.00-10.30 AM EDT / 7.00-7.30 AM PDT.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.

Abstract:

In this webinar, we will explore how Cellectricon, an experienced in vitro CRO, can provide predictive and decision-making data for drug discovery and development in chronic pain.

As neuronal excitability is a hallmark for chronic pain, we will focus on means to use in vitro models to interrogate neuronal function in a high-capacity manner in this webinar. Examples will be given from target identification and validation, where we help Clients to connect genetic findings to nerve function.

We will continue to screening, highlighting our high capacity and reproducibility working with novel in vitro models. We will end by discussing how selection of the right model and species in each step is crucial before progressing molecules to patients.

Presented by:

Paul Karila, CBO

Paul joined the company in 2012 as head of Cellectricon’s Discovery Services and is now responsible for deal-making and business development in his role as CBO. He previously worked at AstraZeneca (AZ) where he held leadership positions at the Departments of Molecular Pharmacology and Neuroscience. At AZ, Paul led teams responsible for target identification/target validation and ion channel and GPCR profiling in LI-LO phase, mainly in chronic pain and neuropsychiatry projects. Prior to joining AZ, Paul was a Postdoctoral Fellow at School of Medicine, University of Pittsburgh, USA, studying neurobiology using electrophysiological methods. He has a PhD in physiology from University of Gothenburg, Sweden.